Dear colleagues at #ESMO26 OncoAlert 🚨 is proud to partner with @AUC3_Official! 📢 The publication is out, Read the article here acsjournals.onlinelibrary.wi… 🌴 JOIN US in sunny Miami, learning from leading experts in #KidneyCancer and #BladderPractice. We had the opportunity to catch up with 🇺🇸 @DrChoueiri to hear more about the publication and the meeting. auc3.com @DrChoueiri, @DrRanaMcKay, @montypal, @DrRosenbergMSK, @Wanling50578056, @Dr_Aggen, @AlbigesL, @apolo_andrea, @OncoBellmunt, @bergsa83, @bilenma, @BraunMDPhD, @drjefstathiou, @shilpaonc, @arihakimi, @HHammersMD, @DrDanielHeng, @MichelleDunno17, @EJonasch, @koshkin85, @advocatekidneys, @UrogerliMD, @SurenaMatinMD, @maughanonc, @BradMcG04, @JoshMeeks, @motzermd, @AndreaNecchi, @SimaPorten, @tompowles1, @brian_rini, @sonpavde, @ChadTangMD, @MichvdHeijden, @VincentWenxinXu, @TiansterZhang, @Mustafajsalehmd, @mzugman #ESMO26 #KidneyCancer #BladderCancer

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results From the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study 🔬 Phase 3 (n=776): TROP2-directed ADC sacituzumab tirumotecan vs physician’s choice (doxorubicin or paclitaxel) in advanced/recurrent endometrial cancer after platinum and anti-PD-(L)1. Dual primary endpoints: PFS and OS. ➡️ Median PFS 7.2 vs 3.9 mo; HR 0.59 (0.50–0.70) ➡️ Median OS 19.0 vs 12.1 mo; HR 0.68 (0.55–0.84) ➡️ ORR 35.1% vs 17.3%; grade ≥3 TRAEs 54.4% vs 41.4% ✅ Authors: significant PFS, OS and ORR improvement with manageable safety, supporting sac-TMT as a new treatment option in this population. #EndometrialCancer 🎙️ Domenica Lorusso (4Sight Made from Abstracts publicly available at the ESMO website)

Join OncoAlert and our collaborators at @mirrorsmed for the 2026 Global Forum in GU Oncology REGISTER HERE: gu-global-forum.org/?utm_sou… HERE is our friend Dr Philippe BARTHÉLÉMY 🇫🇷To Tell us more about this great forum! December 2–5, 2026 Amsterdam, Netherlands This is an excellent opportunity to learn how to translate the latest advances in oncology into your clinical practice. #Prosca26 #BLADDR25 #RENALC26 @BertrandTOMBAL, @Ric_Campi, @achoud72, @bkonety, @lisapic, @Achard_Verane, @MichvdHeijden, @roodvdb, @Zondervan_AUMC, @karolien_goffin

MOIO: Interim Analyses of a Phase III Randomized Non-Inferiority Trial Assessing Reduced Frequency Immune Checkpoint Inhibitors in Responding Patients With Advanced/Metastatic Cancer @SabatierRenaud 🔬 Academic phase III non-inferiority trial (n=340, France): standard IO vs reduced dose intensity (every 3 months) in patients responding after 6 months of IO for advanced solid tumors. ➡️ PFS HR 1.35 (0.9–2.0); median 21.9 vs 25.0 mo; futility boundary exceeded ➡️ OS HR 2.0 (1.1–3.9) with reduced IO ➡️ Grade 3–4 irAEs 9.5% vs 10.5% ✅ Authors: non-inferiority not achieved, no meaningful safety advantage, and a signal of inferior survival; differential effects argue against uniform de-escalation. 🎙️ Gwenaëlle Gravis 👥 Patricia Marino · Daniel Olive · Frédérique Penault-Llorca · Jean-Pierre Delord · Clotilde Simon · Assia Lamrani-Ghaouti · Renaud Sabatier · Joseph Ciccolini · Jean-Marie Boher Pinging our faculty @Lucarecco @Dr_Oncologista @guiandri76 @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @niklas_kluemper @Markuseckstein3 @nataliagandur, @oriolmirallas @ugurozkerim